Latest Herceptin news
Neratinib Not Superior to Trastuzumab in ERBB2-Breast CA
posted April 15th
by modernClinician Editorial Team
by modernClinician Editorial Team
Neratinib-paclitaxel is no better than trastuzumab-paclitaxel for progression-free survival in recurrent and/or metastatic ERBB2-positive breast cancer, although it may delay the onset and reduce the frequency of central nervous system progression, according to a study published online April 14 in JAMA Oncology.
Lapatinib + Trastuzumab May Rapidly Shrink Breast Tumors
posted March 10th
by modernClinician Editorial Team
by modernClinician Editorial Team
The drug combination of lapatinib (Tykerb) and trastuzumab (Herceptin) induces tumor regression or disappearance in 25 percent of human epidermal growth factor receptor 2 (HER2)-positive cancers in 11 days, according to research presented Thursday at the European Breast Cancer Conference, held from March 9 to 11 in Amsterdam.
Editor's Recommendations
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment 
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy .jpg)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers 
Gap Found Between Awareness of Breast Cancer Risk and Risk-Reducing Behavior Related Articles
Financial Incentives Boost Tobacco Abstinence in Underserved Adults 
Exercise Intervention Linked to Improved Attention, Memory in Breast Cancer 
Dense Breast Notification Linked to Increase in Use of Supplemental Ultrasound 
Mammography Trials Yield Excess-Incidence Patterns Consistent With Low Overdiagnosis Monthly Specialist Briefings
Stay Connected
